Medicoeconomic evaluation of hyaluronic acid for knee osteoarthritis in everyday practice: The MESSAGE study
Giret d'Orsay, Geneviève; Mazières, Bernard; Bard, Hervé; Ligier, Marie; Brud, Isabelle; Le Pen, Claude (2007), Medicoeconomic evaluation of hyaluronic acid for knee osteoarthritis in everyday practice: The MESSAGE study, Joint Bone Spine, 74, 5, p. 453–460. http://dx.doi.org/10.1016/j.jbspin.2007.01.037
TypeArticle accepté pour publication ou publié
Journal nameJoint Bone Spine
MetadataShow full item record
Author(s)Giret d'Orsay, Geneviève
Le Pen, Claude
Laboratoire d'Economie de Dauphine [LEDa]
Abstract (EN)Introduction Medicoeconomic data on treatments for osteoarthritis are scant. We investigated the impact of hyaluronic acid therapy on the cost of management of knee osteoarthritis. Our primary objective was to compare medical costs (admissions, outpatient visits, investigations, and treatments) and non-medical costs (sick leaves and transportation) from the perspective of the national health insurance system during the 3 months before and the 6 months after three intraarticular injections of hyaluronic acid. Our secondary objective was to evaluate treatment benefits in terms of pain, function, and quality of life. Methods Observational, multicenter, longitudinal, before-after study of the medical and economic effects of hyaluronic acid therapy for symptomatic knee osteoarthritis. Results Of the 296 assessable patients (mean age, 69 years; 30% with obesity; 65% women), only 5% of patients were withdrawn prematurely from the study. Significant improvements in the Lequesne index were found 3 and 6 months after treatment; the improvement was greater than 50% in over half the patients. Pain and quality-of-life scores improved significantly. Total cost of the disease decreased from €334 for the 3 pretreatment months to €295 and €233 for posttreatment months 1–3 and 4–6, respectively. Conclusion The costs of knee osteoarthritis decreased during the 6 months after Suplasyn® therapy, indicating that the cost of the medication was more than offset by the decreased need for other treatments. Concomitantly, clinical benefits were obtained. Under the conditions of everyday practice, hyaluronic acid may provide medical benefits at an acceptable cost.
Subjects / KeywordsCost-benefit analysis; Medicoeconomic analysis; Knee osteoarthritis; Hyaluronic acid; Suplasyn
Showing items related by title and author.
Étude médicoéconomique d'un acide hyaluronique dans l'arthrose du genou en pratique rhumatologique courante : étude MESSAGE Mazières, Bernard; Bard, Hervé; Ligier, Marie; Bru, Isabelle; Giret d'Orsay, Geneviève; Le Pen, Claude (2007) Article accepté pour publication ou publié
Translating CSR: A comparative study in the emerging activity of corporate social evaluation in France Déjean, Frédérique; Gond, Jean-Pascal; Huault, Isabelle; Leca, Bernard (2006) Communication / Conférence
Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study De Caterina, Raffaele; Kelly, Peter; Monteiro, Pedro; Deharo, Jean Claude; de Asmundis, Carlo; López-de-Sá, Esteban; Weiss, Thomas W.; Waltenberger, Johannes; Steffel, Jan; de Groot, Joris R.; Lévy, Pierre; Bakhai, Ameet; Zierhut, Wolfgang; Laeis, Petra; Reimitz, Paul-Egbert; Kirchhof, Paulus (2019) Article accepté pour publication ou publié
Paul, Christophe; Le Pen, Claude; Fénéron, Delphine; Meyer, Nicolas; Bardoulat, Isabelle; Thiriet, Catherine; Camara, Catherine; Sid-Mohand, D.; Ortonne, J. P. (2010) Article accepté pour publication ou publié